US FDA approves only triple-combination tablet with Jardiance for adults with type 2 diabetes

Eli Lilly

27 January 2020 - Trijardy XR (empagliflozin/linagliptin/metformin hydrochloride extended release tablets) is a once-daily therapy combining three well-established treatments in one pill.

The U.S. FDA has approved Trijardy XR (empagliflozin/linagliptin/metformin hydrochloride extended release tablets) to lower blood sugar in adults with type 2 diabetes, along with diet and exercise. Trijardy XR provides three type 2 diabetes medicines in one pill, including Jardiance (empagliflozin), Tradjenta® (linagliptin) and metformin hydrochloride extended release. 

Trijardy XR is marketed by Boehringer Ingelheim and Eli Lilly.

Read Eli Lilly press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , US